PROTAGENE CGT GMBH

Their core work

Protagene CGT GmbH (formerly Genewerk GmbH) is a Heidelberg-based biotech SME specializing in cell and gene therapy (CGT) product development. Their work centers on designing and advancing genetic medicines for rare primary immunodeficiencies — in particular, Severe Combined Immunodeficiency (SCID), a life-threatening condition where patients are born without a functional immune system. In EU projects they contribute therapeutic development expertise, including stem-cell-based gene correction approaches, alongside academic and clinical partners. The company name change from Genewerk to Protagene CGT signals a deliberate commercial repositioning toward the cell and gene therapy industry.

What they specialise in

How they've shifted over time

The organisation's H2020 track begins with SCIDNET (2016–2019), a broad consortium developing genetic medicines for multiple SCID subtypes, where gene therapy was the implied technology but not yet the headline keyword. By RECOMB (2018–2024), the focus had sharpened to a specific disease mechanism — recombination deficiency — and the approach is explicitly named as stem-cell based gene therapy, reflecting maturation from concept to platform. The trajectory is one of progressive specialisation: broader disease category first, then deeper mechanistic and technological commitment, consistent with an SME advancing a proprietary or partnered CGT platform toward clinical validation.

They are moving from broad rare-disease gene therapy research toward a defined stem-cell-based CGT platform, suggesting that future collaborations will likely focus on clinical translation, manufacturing scale-up, or regulatory development of SCID gene therapies.

How they like to work

Protagene CGT has participated exclusively as a consortium partner — never as project coordinator — across both projects, which is typical for a small specialist SME that brings proprietary technology or niche expertise rather than administrative leadership. Despite only two projects, they have accumulated 21 unique partners across 10 countries, an unusually broad network that suggests they are embedded in a well-connected rare disease and CGT research community. This profile fits an organisation that works as a focused technical contributor within larger academic-clinical-industry consortia rather than one that drives project strategy.

With 21 consortium partners across 10 countries from just two projects, Protagene CGT is connected to a wide European network concentrated in health research and CGT — typical of pan-European rare disease consortia that draw on immunology centres, gene therapy labs, and clinical sites across multiple member states. No single geographic cluster dominates, reflecting the multinational structure of EU rare disease programmes.

What sets them apart

Protagene CGT occupies a rare niche: a private SME — not an academic spinout or CRO — with a track record specifically in gene therapy for SCID, one of the most technically demanding targets in rare disease medicine. Located in Heidelberg, one of Europe's densest biomedical clusters (DKFZ, EMBL, Heidelberg University Hospital), they likely benefit from proximity to world-class immunology and gene therapy infrastructure. For a consortium building a gene or cell therapy programme targeting primary immunodeficiencies, they represent a commercially minded specialist who can bridge research and product development.

Highlights from their portfolio

• RECOMB
  A six-year project (2018–2024) that represents their most recent and longest EU engagement, focused on a specific SCID subtype using stem-cell gene therapy — the closest to a clinical translation programme in their portfolio.
• SCIDNET
  Their first EU project and the largest by EC funding (EUR 699,750), establishing their position in a pan-European SCID genetics network and providing the foundation for subsequent deeper specialisation.